Pasithea Therapeutics Corp.
KTTAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001841330
No open-market purchases or sales by Pasithea Therapeutics Corp. insiders were filed in the last 90 days; 6 institutions reported holding it in 13F filings for Q2 2026, worth $3.18K in total; no superinvestor holds it.
Other share classesKTTA
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +1 vs. previous quarter
- 6
- 13F valueReported value at the end of Q2 2026
- $3.18K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding KTTAW, Q2 2026
No superinvestor reported holding KTTAW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Pasithea Therapeutics Corp. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 22, 2026 (view filing) | Jun 17 | 5 days | Coastlands Capital LP10% Owner | PPurchase | +100.0K | $0.53 | +$53.0K | +2.7%3.84M after | |
| Dec 1, 2025 (view filing) | Nov 28 | 3 days | Steinman LawrenceDirector | PPurchase | +133.3K | $0.75 | +$100.0K | +200.9%199.7K after | |
| Dec 1, 2025 (view filing) | Nov 28 | 3 days | Marques TiagoChief Executive Officer | PPurchase | +33.3K | $0.75 | +$25.0K | +83.3%73.3K after | |
| Dec 1, 2025 (view filing) | Nov 28 | 3 days | Dumesnil SimonDirector | PPurchase | +33.3K | $0.75 | +$25.0K | +1,333.3%35.8K after | |
| May 14, 2025 (view filing) | May 12 | 2 days | Marques TiagoChief Executive Officer | SSale | −960 | $0.83 | −$796.8 | −2.3%40.0K after | |
| Jun 6, 2023 (view filing)9:00 PM ET | Jun 2 | 4 days | Steinman LawrenceDirector | PPurchase | +30.0K | $0.431 | +$12.9K | +2.3%1.33M after | |
| Oct 19, 2022 (view filing)5:29 PM ET | Oct 17 | 2 days | Delaney David and 2 othersOther: Member of 10% owner group | PPurchase | +1.00K | $1.11 | +$1.11K | +0.4%227.5K after | |
| Sep 30, 2022 (view filing)4:36 PM ET | Sep 28-29 | 2 days | Camac Fund, LP and 3 othersOther: Member of 10% owner group | PPurchase | +64.4K | $1.19 | +$76.3K | +3.7%1.79M after | 2 lots |
| Sep 6, 2022 (view filing)5:03 PM ET | Sep 1-6 | 5 days | Camac Fund, LP and 3 othersOther: Member of 10% owner group | PPurchase | +88.9K | $1.13 | +$100.4K | +5.4%1.72M after | 3 lots |
| Aug 31, 2022 (view filing)4:32 PM ET | Aug 29-30 | 2 days | Camac Fund, LP and 3 othersOther: Member of 10% owner group | PPurchase | +22.8K | $1.15 | +$26.3K | +1.4%1.64M after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Pasithea Therapeutics Corp. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Kepos Capital LP | 334,600 | $2.00K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 57,539 | $397 | 0.00% | +1,895+3.4% | Added |
| Armistice Capital, LLC | 50,000 | $345 | 0.00% | 00.0% | Unchanged |
| Marex Group plc | 25,000 | $223 | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 24,293 | $216 | 0.00% | +24,293 | New |
| Clear Street Group Inc. | 380 | $3 | 0.00% | +380 | New |